PGx is a rapidly developing cross-disciplinary field of molecular biology, pharmacology, bio- and health informatics, translational and clinical research. It studies how a person’s genes affect the response to drug therapy. PGx testing identifies and manages the differences in the response among individuals receiving the same medication and dose. PGx is quickly becoming one of the most significant pillars of contemporary precision medicine and current clinical standards for PGx testing offers the potential for individualized actionable results in over 90% of patients.
This Research Topic, titled Advances in Pharmacogenomics, Basic, Translational and Clinical, aims to present and summarize the enormous progress that has occurred in translational research and the clinical implementation of PGx testing as well as offer an outlook to the future of PGx applications.
We invite original research and reviews describing the development, implementation, application and advances of PGx testing in the clinical setting.
Please note that:
- If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities, and additional clinical information and assessment of clinical response/effects should be included.
- If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided.
- Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
- Original studies analyzing published data or public databases, with no further experimental confirmation or replication, will not be included in this Research Topic.
PGx is a rapidly developing cross-disciplinary field of molecular biology, pharmacology, bio- and health informatics, translational and clinical research. It studies how a person’s genes affect the response to drug therapy. PGx testing identifies and manages the differences in the response among individuals receiving the same medication and dose. PGx is quickly becoming one of the most significant pillars of contemporary precision medicine and current clinical standards for PGx testing offers the potential for individualized actionable results in over 90% of patients.
This Research Topic, titled Advances in Pharmacogenomics, Basic, Translational and Clinical, aims to present and summarize the enormous progress that has occurred in translational research and the clinical implementation of PGx testing as well as offer an outlook to the future of PGx applications.
We invite original research and reviews describing the development, implementation, application and advances of PGx testing in the clinical setting.
Please note that:
- If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities, and additional clinical information and assessment of clinical response/effects should be included.
- If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided.
- Studies related to natural compounds, herbal extracts, or traditional medicine products, will not be included in this Research Topic.
- Original studies analyzing published data or public databases, with no further experimental confirmation or replication, will not be included in this Research Topic.